The Phase I study of anti-CD22 CAR T cells, sponsored by the National Cancer Institute, targets pediatric and young adult patients with recurrent or refractory CD22-expressing B cell malignancies. Given the high expression of CD22 in pediatric B-precursor acute lymphoblastic leukemia (ALL), this therapy addresses a significant unmet need in a patient population with limited treatment options. The competitive landscape includes existing CAR T therapies targeting CD19, but the emergence of CD22 as a target may provide a strategic advantage in cases of CD19-negative escape. The successful demonstration of safety and efficacy could position this asset favorably for further development and potential commercialization, particularly in the pediatric oncology market, which is increasingly focused on innovative therapies. Diligence considerations should include assessment of manufacturing capabilities, regulatory pathways, and potential partnerships for broader market access.